Merete Lund Hetland
University of Copenhagen
Publications 398
#1Brigitte Michelsen (Hospital of Southern Norway)H-Index: 5
Last.Ziga RotarH-Index: 7
view all 31 authors...
#2Karl Bang Christensen (UCPH: University of Copenhagen)H-Index: 38
Last.Merete Lund Hetland (UCPH: University of Copenhagen)H-Index: 44
view all 4 authors...
Objectives: The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a widely used patient-reported outcome for functional disability in rheumatoid arthritis (RA). Minimal clinical...
#1Stinne Ravn Greisen (AU: Aarhus University)H-Index: 7
#2Tue Wenzel Kragstrup (AU: Aarhus University)H-Index: 10
Last.Bent Deleuran (AU: Aarhus University)H-Index: 32
view all 19 authors...
Abstract Objective Active rheumatoid arthritis (RA) is accompanied by increased appendicular and axial bone loss, closely associated to the degree of inflammation. The programmed death-1 (PD-1) pathway is important for maintaining peripheral tolerance, and its ligand PD-L2 has recently been associated with bone morphogenetic protein activity. Here, we report that PD-L2 plays a central role in RA osteoimmunology. Methods Femoral bone mineral density (BMD) and trabecular bone microstructure were e...
#1Nina O Nathan (Copenhagen University Hospital)
#2Lina Steinrud Mørch (Copenhagen University Hospital)H-Index: 4
Last.Ane Lilleøre Rom (Copenhagen University Hospital)H-Index: 4
view all 7 authors...
#1Kathrine Lederballe Grøn (UCPH: University of Copenhagen)H-Index: 3
#2B. Glintborg (UCPH: University of Copenhagen)H-Index: 7
Last.Merete Lund Hetland (UCPH: University of Copenhagen)H-Index: 44
view all 8 authors...
#1Lykke Midtbøll Ørnbjerg (Rigshospitalet)H-Index: 8
#2Cecilie Heegaard Brahe (Rigshospitalet)H-Index: 1
Last.Mikkel ØstergaardH-Index: 75
view all 32 authors...
Objective To study drug retention and response rates in patients with axial spondyloarthritis (axSpA) initiating a first tumour necrosis factor inhibitor (TNFi). Methods Data from 12 European registries, prospectively collected in routine care, were pooled. TNFi retention rates (Kaplan-Meier statistics), Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive disease ( Results A first TNFi was initiated in 24 195 axSpA patients. Heterogeneity of baseline characteristics between registries...
2 CitationsSource
Last.Merete Lund Hetland (UCPH: University of Copenhagen)H-Index: 44
view all 32 authors...
OBJECTIVE To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naive patients with PsA. METHODS Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] a...
#1Denis Mongin (Geneva College)H-Index: 1
#2Kim Lauper (Geneva College)H-Index: 4
Last.Delphine S. Courvoisier (Geneva College)H-Index: 28
view all 11 authors...
Objective To compare several methods of missing data imputation for function (Health Assessment Questionnaire) and for disease activity (Disease Activity Score-28 and Clinical Disease Activity Index) in rheumatoid arthritis (RA) patients. Methods One thousand RA patients from observational cohort studies with complete data for function and disease activity at baseline, 6, 12 and 24 months were selected to conduct a simulation study. Values were deleted at random or following a predicted attritio...
1 CitationsSource
#1Ulf Lindström (University of Gothenburg)H-Index: 5
#2Bente GlintborgH-Index: 12
Last.Lennart T. H. Jacobsson (University of Gothenburg)H-Index: 39
view all 12 authors...
Objective Although clinical trials support equivalence of originator products and biosimilars for etanercept and infliximab, real-world studies among biologics-naive patients with spondyloarthritis (SpA) are lacking. The objectives were to compare treatment retention in biologics-naive patients with SpA starting either the originator product or a biosimilar of infliximab and etanercept, and to explore the baseline characteristics of these patients. Methods Patients with SpA (ankylosing spondylit...